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Sudden corona O, death b~ patients with coronary am'rr dLw~,,e remmns . malor 
medical problem it; most indmtnalized natum.~ and in most i~s+tam-(,~ i~ +~.w~<'iated 
with the unexpected development of  ventricuhtr fibrillation. De.wite the development 
oft new anti-arrhythmic drugs, flea, ifl any. are suitahh" for long-term prophyhictw 
application and none were developed spec~caUy .for tlw prerentum o.f vemncular 
fibrillation. This article discusses the importmwe oft the predmical phase of drug 
development in an attempt to flocus on those electrophysiologicai mechan[~nts which 
superimpo'e upon a wdnerable mvocardium thus leading to, the onset o] ledtM 
arrhythmias, it is agab~st this background that potentially usehd pharma( oh~gical 
inten,entions must be as~ssed ifl specific therapy for die prevention ot sudden 
coronao, death is to become a reality. 
What seems to be the content? 
The morbid statistics for the United 
States alone would sug,_-est that there 
are 400000 victims each year who 
succumb to sudden coronary death. The 
very suddenness of, and the electro- 
cardiographic observations prior to or 
accompanying the fatal event, lead to 
the assumption that cardiac arrhythmias 
are the cause of death, either ventricular 
arrest or ventricular fibrillation, with the 
majority of patients having underlying 
heart disease. Mobile coronary care 
units and rapid response emergency 
systems have been developed as an 
approach to aiding ~ictims of out-of- 
hospital ventricular fibrillation and the 
results of such efforts at resuscitation 
have demonstrated that many individuals 
can be returned to a productive lit'e, 
although the continued pre~nce of their 
underlying coronary artery di~ase 
make them vulnerable to a subsequent 
event in which lethal arrhythmias may 
develop suddenly and unexpectedly. 
There is sufficient clinical evidence to' 
indicate that the majority of episodes of 
ventricular fibrillation are 'primary" 
dysrhythmic events and not secondary 
to acute myocardial infarction. 
There is a strong association bctmeen 
certain angiographic and functional 
abnormalities and the development of 
ventricular fibrillation and recurrent 
ventricular fibrillation. In recent yea~.  
medical attention has been focu.~d 
upon identifying patients is+ha are vul- 
nerable to the development of life- 
threatening arrh,,lhmias. Thus. suni+'ors 
of myocardial infarction and that identi- 
fiable segment of the asymptomatic 
population with an ominous risk profile 
are demonstrably at very high risk of 
sudden death with at least t~o-thlrd,, of 
the deaths occurring in the first hour. 
If an impact is to be made upon the 
high mortality due to sudden coronar~ 
deatl,., it must depend upon the recog- 
nitiun and treatment of those at risk. 
with the goal of preventing tentricular 
fibrillation bv a prophylactic theraix.'utic 
regimen. 
Present status or i ~ m n a e o l o g k ~  
therap? 
A comprehensive review of the 
pharmacological, electrophysiological 
and clinical applications of many of the 
newer, potentially useful, anti-arrhythmic 
agents has appeared recently t. Despite 
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exten~l~C dlnic.il ',futile.. it I,, n4~! l~,qblc 
1¢) dcmoflslratt: thal ark ° qlr m,n+ ,~ the 
netter ;l~ents l~,~.s,,~+,,, dig+ prot]tl,~" d', 
l~.,ing the iekoal ag+:nl for the prc~cnlJ~m 
el  ~ n  cot, man  &0+,ill Ret+°~:n! ,,|,|dlt. ~. 
ttith amK~darone: ' ho~ctcr. In++nI¢ 
r e a ~ i A  f o r  o p l i m l ~ m  Ill +It+~,A ++| th+: in tc t -  
~.%ti,lg lC<~+llI ~, ohlaln+:d in p, dwnt++ al 
high I+P,k el +,udden c+Jr,+na;++ dc.i lh 
l ~'spn+: i15 rel~ wlcd ¢Itk+at+x. am++ +tl,.+,n,- 
is Iimit~'d in I t  ~. mudesprcaJ +rod hm~ 
tetra appllealion bs, the d¢,.eloprncnt +~i 
untk~irable +.xnam.'t+us. m:ural+ ~:ular and 
hormonal ,+tde-etfl:~l+, It max t~: adxan- 
lag¢ou,+ to t:xplor¢ i~qenl,al Ihula|'~:ul=c 
lx-nefils of ch~:h  related derl+at,,+;>, oi 
umiodaronc in an attempt to aehtcx¢ 
similar electrophysiol, l~cal eflech. ~,ith- 
out the toxic effects noted pre+lOu,+l.~ 
A numlx-r of recent 5tudie~, ha,,+." 
demonstrated thai the admml,,trat,on o+ 
J3-adrenergic receptor bh~-kln~ agent,, 
could reduce the incidence ot pro, t- 
hospital sudden coronart death in 
patients ~'ho had experienced a m~,t+- 
cardml infarction in the [3-Bh~:kcr 
Heart Attack Tnai tBHAT)  supported 
by the Na.,.ional Institutes of Health. 
383  "~ patient~ were random,ted to 
therap) with either 40 mg propranolol. 
or placebo, three time~ dailx, start;+ ~ at 
a mean time of 13N daxs from the time 
O[ m++t~.'ardial i n t a rc t , on .  After M) 
months, the control group had a u ~,++ 
monahtx as compared with " II + , ,t~+on~ 
propranolol-treated patients, thus +up- 
porting the concept thal mortalitx in the 
post-myocardial infarct patient carl Ix" 
reduced +~,ith the institut:on of appro- 
pnate t h e r a p )  An earlier. Nor~egmn 
Mu!ticemer Trial mith the ~-receptor 
blocking agent, timolol, demonstrated a 
potential benefit in reducing the rate at 
reinfarctlon and the incidence of ,,uddcn 
death m patients m the tx~st-ho',pit,d 
pha,~ t,f mx t~:ardtal infarction. 
At present, it t+~ s,llC It+ co[ICtt lde that 
there is uncerl+tintx rt.'l~+irdiflg the 
ntcchu,,ism l+x which ~3-adrcncrgic re- 
copter blt~.-king drugs exert their ants- 
arrh)tnmlc effects in the i~'hemiealh 
injured heart and +~.+hether or not the~. 
agent.~ tan dccream the inctdcnct: of sud- 
den coromtrv death in all patients at risk 
of experie:tcing a lethal arrh+lhmic event. 
The potential implications of them 
studies are significant in ;hat they in- 
dicate that pharmacological inter~ell- 
tions can prott.~ct the i~hemic heart 
against the sudden onset of ventricular 
fibrillation, thus allo~lng more time for 
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the institution of medical assistance. 
However. the interruption of adrencrgic 
support to the heart may not be without 
hazard in those patients who require a 
degree of cardiac inotropic and chrono- 
tropic stimulus during the acute phase of 
myocardial infarction. Such patients 
may be subjected to a higher incidence 
of cardiogenic shock and bradyarrhyth- 
mias. Furthermore, 13-adrenergic re- 
ceptor blockade might preclude the suc- 
cessful use of inotropic agents, such as 
norepinephrine, dopamine, dobutamine, 
etc. Other limitations to the use ~f 13- 
adrenergic receptor blocking agents 
would be in those patients with obstruc- 
tive airway disease and in those with 
heart failure. 
Those post-myocardial infarction 
patients who are not considered to be 
suitable candidates for the administration 
of IS-receptor blocking agents could 
have other available anti-arrhythmic 
dru~ administered but. unfortunately, 
they too are limited in their application 
because of toxicity as,~yziated with their 
long-term use. An important fact to 
recognize is that. despite their demon- 
strated efficacy as anti-arrhythmic drugs, 
oarrently available agents and many of 
the newer drugs under clinical investi- 
gation have not been shown to be effec- 
tive in the prevention of sudden coronary 
death. Furthermore. the effectiveness of 
a chronically administered drug in pro- 
tecting the ambulatoD' patient from 
sudden coronary death can not be pre- 
dicted from short-term observations 
made on hospitalized patients with 
acute myocardial infarction, since there 
are no reasons to believe that the electro- 
physiological disturbances leading to 
ventricutar fibrillation are the same in 
both situation~. 
May et  ai. ~ recently reviewed the 
results of 14 clinical trials involfing 3 6Z ~, 
patients with documented myocardial 
infarction who were treated with one of 
four anti-arrh~ahmic drugs: quinidine. 
procainamide, disopyramide or lidocaine. 
Despite t.he fact that each agent has 
:~een reported to suppress ventricular 
arrhvthmias in the acute phase of myo- 
cardial infarction, and lidocaine may 
reduce ~he incidence of in-hospital ven- 
tricular fibrillattion, not one of the trials 
has demonstrated that suppression of 
ventricular premature beats is ac- 
companied by a statistically significant 
reduction in overall mortality. 
~ t e s ~  procedor~s 
for the dinical evaluation of 
Electrophysiological abnormalities can 
be demonstrated in a large majority of 
patients who have sunvived an episode 
ot out-of-hospital cardiac an'est not 
associated with acute myocardial in- 
farction. Programmed electrical stimu- 
lation is capable of eliciting ventricular 
tachycardias in most of these patients, 
suggesting the continued presence of an 
electrically unstable myocardial sub- 
strate. On the other hand, electrically 
inducible ventricular tachycardia is 
rarely, if eveL observed in patients who 
do not have structural hear~ di~ase. 
thus illustrating the importance of a 
vulnerable substrate for the development 
of a re-entrant ta,chyarrhythmia. 
The provocative testing procedure of 
programmed electrical stimulation has 
been applied to the evaluation of drug 
treatment regimens in patients with re- 
current ventricular tachyarrhythmias. 
The use of an electrophysiological pro- 
tocol for drug selection is based on 
several assumptions: (l) the tachycardia 
produced in the laboratory by pro- 
grammed stimulation is identical to the 
clinical tachyarrhythmia; (2) the respense 
to drug therapy in the laboratory, predicts 
the clinical response: (3) the ability to 
prevent an electrically induced ven- 
tricular tachycardia by drug treatmem 
predicts the inability of t~e heart to 
develop ventricular fibrillation, especially 
if an i~hemic episode is superimposed 
upon a vulnerable substrate. Thus, one 
is not certain that Ihe prevention of 
electrically-induced arrhvthmias by drug 
therapy is synonym,.~us w~th the pre- 
vention of sudden coronary death. 
Whereas the first and second assump- 
tions may have been established, the 
third has not, since an acute ischemic 
episode is not part of the testing pro- 
cedure and the true efficacy of a drug 
intervention can only be determined by 
Iook~ng at its potential to prevent sudden 
coronary death; an end-point seldom 
achieved during provocative testing pro- 
cedures. It may also be true that a drug 
which fidls to prevent the initiation of 
tachyarrhythmia by programmed elec- 
trical stimulation may still successfully 
prevent a spontaneous recurrence. This 
would be especially true of those agents 
which accumulate in myocardial tissue 
over time and show little correlation 
between concentration of drug in the 
plasma and therapeutic efficacy, e.g. 
amiodarone, propranolol and bretyik~.a. 
Furthermore, the failure to recognize 
the formation of active metabolites as 
participating in the overall pharmaco- 
logical and electrophysiological effects 
of an intervention could cast additional 
doubt on the value of  a 'therapeutic 
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plasma concentration' as a guide to 
adequate therapy unless one is familiar 
with the metabolic praducts and has 
approprNate means of quantitating them 
in plasma. 
What needs to be aecomplished? 
The previous discussi,m was intended 
to emphasize the imFortance of the 
problem of sudden coronary death and 
to suggest that a pharmacological 
approach may make a s,ignificant impact 
upon the mortality rate, if indeed ven- 
tricular fibrillation constitutes the ter- 
minal electrophysiological event. In 
reviewing the results of long-term sup- 
pressive therapy for the prevention of 
sudden cardiac death, Lovell 5 stated that 
'non-specific long-term prophylactic use 
of existing drags holds less promise than 
appeared at one time to be the case. It 
may be that tolerable drugs which are 
highly effective in inhibiting ventricular 
fibrillation when given long-term will be 
developed, and this is a worthwhile aim'. 
Despite the world-wide need for a 
truly antifibriilatory drug, there has 
been relatively little effort directed to- 
wards this end. At present, the anti- 
arrhythmic drugs available in the USA 
for chronic management of patients with 
life-threatening arrhythmias are quini- 
dine, procainamide, disopyramide, pro- 
pranolol, timolol, metoprolol, and 
phenytoin. None is considered entirely 
suitable for long-term prophylactic use 
in the prevention of sudden coronary 
death. Of the new agents, namely 
amiodarone, aprindine, betanidine. 
tocainide, mexiletine, encainide, meo- 
bentine, fleca~de, and pirmenol, none is 
known specifically to prevent ventricular 
fibrillation in either the experimental 
animal or in man. Furthermore, it is 
most disappointing to note that the 
newer anti-arrhythmic drugs were not 
developed specifically for the problem 
under consideration. There are limited 
animal data available with respect to 
these agents and already several are 
proving to have serious toxic effects 
associated with their long-term use. This 
is especially true of amiodarone, which, 
despite its clinical efficacy as an anti- 
fibrillatow agent, has produced signifi- 
cant side-effects, so as to limit its use to 
the most seriously ill patients. 
The approach to finding an effective 
antifibrillatory drug in contras~ to an 
anti-arrhythmic drug for the prevention 
of sudden cardiac death has been one of 
mere chance alone, and it is doubtful 
that this 'hit-and-miss" method will ever 
prove successful. The fact that several 
pharmacological interventions have 
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been shown both experimentally and 
clinicall~ to exert an antifibrilhitory 
effect 6-" should cause cardiovascular 
pharmacologists to exert greater effort 
towards the development of more useful 
and acceptable agents for the prevention 
of sudden coronary death. Therefore, if 
substantial progress is to be made, it will 
require a greater emphasis upon the 
preclinical development of pharmaco- 
logical agents, which, o n  the basis of in- 
v i v o  and # M ' i t r o  electrophysiologicai 
studies, provide evidence for possessing 
activity which could allow them to be 
classified as being antifibrillat~)ry. 
W h e r e  c a n  o n e  start? 
A major problem in designing them- 
peutic approaches to sudden coronary 
death has been the limitation of appro- 
priate animal models. The bulk of tbe 
available data on the electrophysioiogical 
properties of current anti-arrhvthmic 
drugs was derived from i n - v i t r o  studies 
on 'normal' cardiac muscle from a variety 
of animal species. Within recent years 
some effort has been made to employ 
ischemically injured myocardial tissue in 
electrophysiological studies i n - v i t ro .  
The description of the mechanisms 
for arrhythmias and conduction disturb- 
ances observed in intact hearts has been 
based primarily on electrophysiological 
data obtained in isolated heart muscle 
or in intact hearts studied many hours or 
days after isehemic injuD, or in intact 
animal preparations in which cardiac 
arrhythmias are induced through the 
administration of digitalis glycosides or 
other cardiotoxic-arrhythmogenic agents. 
Several methods have been developed 
for producing animal models with chronic 
myocardial ischemic injury, in which 
ventricular arrhythmias develop spon- 
taneously or in response to programmed 
electrical stimulation~(~3. However, 
these models do not provide an oppor- 
tunity to examine the electrophysiological 
events preceding the development of 
ventricular fibrillation or to study 
pharmacological interventions for the 
prevention of life-threatening arrhyth- 
mias. In considering the problem of 
sudden coronary death, it would be 
advantageous to employ a chronic 
animal model in which a previous myo- 
cardial infarction has left the heart sus- 
ceptible to the development of re- 
entrant ventricular tachyarrhythmia and 
in which ventricular fibrillation will 
occur in response to a new, albeit tran- 
sient, ischemic insult, insufficient to 
produce myocardial infarction, but 
which results in sudden coronary death. 
The ideal animal model for the study 
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of pharmacological interventions for the 
prevention of life-threatening arrhyth- 
mias should be based on the knowledge 
that the incidence of primary,.' ventricular 
fibrillation is maximal in the first few 
minutes after an acute ischemic event 
and thereafter decays exponentially. 
and that the majority of patients have 
ventricular fibrillation because of coro- 
nary. artery disease, but without acute 
myocardial infarction as the precipitating 
event. 
Our laboratory has recently described 
a conscious canine model ¢~ which is 
susceptible to the induction of ven- 
tricular tachyarrh)¢hmias by programmed 
electrical stimulation and which possesses 
the characteristics stated above so that 
ventricular fibrillation (sudden coronary 
death) develops in response to a tran- 
sient ig'hemic event which is superim- 
posed on a ,, .~ntricular myocardium with 
a previous history, of ischemic in jut" 
(Fig. 1). We have been able to demon- 
strate that disorganization of the cardiac 
rhythm and the development of ven- 
trieular fibrillation in response to tran- 
sient regiotml ischemia is unlikely to 
occur in the absence of previous mxo- 
cardial ischemic injury, su~.zesting that 
disorganization of the cardiac rh~lhm is 
more likely to t~.'cur in a ventncle which 
serves as a proper substrate for initiating 
and maintaining a rhythm callable of 
degenerating into ventncular fibrillation. 
The mode: permits one to demunstrate 
the existence of c,_,nduction deicers in 
the epicardium of the infarcted myo- 
cardial region, suggesting that a re- 
entrant mechanism is responsible for the 
tachvarrhvthmias x~hich occur in re- 
sponse to programmed electrical stimu- 
lation. Thus. the animal model in which 
the heart has beea subjected to a pre,,- 
ious infarction exhibits man~ similar 
electrophysiological charactenstic:~ to 
the human post-infarcted heart. It is 
susceptible to the induction of ,~entncular 
tachycardia by provt~ative electrical 
stimulation and it can develop ventriculai: 
fibrillation as a result of a superimposed 
transient ischemic evem (Fig. t). In our 
laboratory, untreated control animals 
have a ~1% incidence of "sudden 
coronary, death'. Pretreatment with 
bretylium ~s, pranolium ~t', amiodarone. 
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Fig. 2. Two groups a.f antmal; were Wtblected to the test pnn'edure de,cribcd m F(.¢. i. The control group 
treated with saline diaplaved a i00c4 derelopment of ventncular t~bn/l, uon within 8 h qf application of the 
anrMM current zo the .tnrimal su~.ace o/ the circunJ)qe.t corona.'3." artery. The animals pretreated with UM- 
272 had a 00~ mortMity rare. with the remaining animals suniving tq, to aw end qf the study protocol, at 
which point the., were sacrificed and examination of  the circumflex corona O" aner)" showed a tondh" 
cKclg~iv~" thrombus m the leyi circumflex corona O" arteo'. Fh,~,.. pretreatment with UM-272 allowed 40e¢ 
o/ the ammab to surt'ive desptw extensive ischemic in/t, O" to aw left tennicular rm,'ocardium. The animal 
m~lel o/.,udden corona~, demh mat" ser~'e as ,m important approach to the predirrica! ~sessment of  anti- 
in tlammato O" drugs. 
or nadolol~7 provides significant protec- 
tion (40--80%) from ventricular fibril- 
lation in animals subjected to the test 
procedure (Fig. 2). Ouinidine. however. 
given in dosages which achieved plasma 
concentrations equivalent to those used 
din:ically, was without a protective 
action ts. Furthermore, we could not 
demonstrate a correlation between the 
ability of a drug to prevent ventricular 
fib~lation and to suppress induction of 
ven'tricular tachycardia by programmed 
electrical stimulation. This was particu- 
larly true with respect to amiodarone. 
On the other hand, quinidine prevented 
t|:e induction of ventricular arrhythmias 
by programmed electrical stimulation, 
bm was without benefit in preventing 
ventricular fibrillation in our animal 
rm~lel of sudden coronary death. 
We recognize the difficulty in extra- 
polating from the animal experiment to 
the clinical situation of sudden coronexy 
death in man. However,  it has become 
obvious that most anti-arrhythmi¢ ~rugs 
h~r,,e been, or  are evaluated using /n- 
v/tro or in -v ivo  m o d e l s  which have littie, 
if any, relationship to the clinical patho- 
physiological situation associated with 
sudden coronary death. Thus, animal 
models such as the one being used in 
our laboratory should provide a new 
approach to the predinicai assessment 
of pharmacological interventions in- 
tended specifically four the prevention of 
ventriodar fibrillation and the prevention 
of sudden coronary deaih. The final 
analysis of a drug's potential worth will 
depend,  as usual, upon appropriate 
clinical testing in patients who are at risk 
of developing sudden and unexpected 
life-threatening arrhythmias and/or 
ventricular fibrillation, rather than em- 
ploying the more expedient and less 
dependable approach of ,evaluating new 
agents for their ability to reduce the 
frequency and/or complexity of ven- 
tricular premature depolarizations. 
Substantial pro~ess  has been made in 
recent years with respect to identifying 
subsets of patients who are at risk of 
sudden coronary death. Both surgical 
and electrical means of preventing sud- 
den coronary death in the. most difficult- 
to-manage patient groups have been 
attempted with impressive results. How- 
ever, there continues to exist a need for 
an increased priority to the development 
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of more reliable and effective therapeutic 
agents capable of preventing ventricular 
fibrillation. The challenge is formidable, 
but one which can be met through the use 
of relevant animal models for the pre- 
clinical testing of Ix~tential theralxutic 
interventions and appropriate end points 
to determine clinical efficacy in a patient 
population known to be at an increased 
risk of sudden coronary death. 
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